Peptide Cycle Planning: How Researchers Structure On/Off Protocols

Disclaimer: This guide is for research and educational purposes only. It is not medical advice. Research peptides are not approved by the FDA for human use. Consult a licensed healthcare professional before using any injectable compound.

One of the fundamental design decisions in any peptide research protocol is how long to administer a compound and when to pause. This is typically called "cycle planning" — structuring the on (active) and off (pause) phases of a research protocol.

Cycle planning serves two purposes: it reflects the biology of receptor sensitivity (peptide receptors can down-regulate with continuous stimulation), and it mirrors how most published protocols are structured, allowing better alignment with the research literature.

---

Why Cycles Matter in Research

Most biological signaling systems adapt to persistent stimulation. Receptors that are continuously activated by the same ligand will down-regulate — reducing their density or sensitivity to maintain homeostasis. This is observed across endocrine, neurotransmitter, and growth factor receptor systems.

For peptides that work through specific receptors:

• GHRPs (e.g., ipamorelin): Continuous stimulation of the ghrelin receptor can lead to diminishing GH response over time. Periodic breaks allow receptor sensitivity to recover.
• GHRH analogs (e.g., CJC-1295): Similar receptor adaptation concerns apply to the GHRH receptor.
• Healing peptides (e.g., BPC-157, TB-500): The rationale for cycling here is less established — some researchers use these continuously; others cycle to match their research design or as a general precaution.

The on/off cycle also allows for cleaner data collection in research contexts — outcomes can be compared during active and non-active phases.

---

Common Cycle Structures

No universally standardized cycle structure exists across the literature — published protocols vary. The following structures are those most commonly referenced in research and community documentation:

4 weeks on / 2 weeks off (4/2)

• Common for compounds with faster-acting effects
• Allows more frequent research periods within a calendar year
• Typically used with healing peptides like BPC-157 when targeting specific tissue repair research

8 weeks on / 4 weeks off (8/4)

• Common for GH axis peptides (ipamorelin, CJC-1295)
• Provides a longer observation window within each active phase
• Off period approximates half the active period length

Continuous use (no defined off period)

• Used in some BPC-157 and TB-500 protocols, particularly in long-term research designs
• Not universally supported — receptor desensitization rationale suggests some subjects may benefit from breaks regardless

5 days on / 2 days off (weekday dosing)

• Sometimes used as a practical variant that aligns with work schedules
• Whether the 2-day weekend break is biologically meaningful is not well-established

The right structure depends on the compound, the research objective, and the specific protocol being followed.

---

Combination Research: Stacking Protocols

Many researchers study multiple peptides simultaneously or in sequence. This is sometimes called "stacking." Common combinations found in the research literature and documentation:

BPC-157 + TB-500 These two are among the most frequently combined healing peptides. BPC-157 research focuses heavily on gut and tendon tissue; TB-500 research on systemic tissue repair and angiogenesis. The combination is studied for additive or complementary tissue repair effects.

Ipamorelin + CJC-1295 (without DAC) The most common GH axis combination. Ipamorelin provides ghrelin receptor stimulation; CJC-1295 provides GHRH pathway stimulation. Research has demonstrated synergistic GH pulse amplification when both are injected together.

BPC-157 / TB-500 + GH Axis peptides Some researchers study healing peptides alongside GH axis peptides based on the premise that GH supports anabolic and repair processes. These are run as concurrent protocols.

When studying multiple peptides, each compound:

• Has its own separate reconstituted vial
• Is calculated individually
• May have a different dosing schedule
• Should be tracked separately in research logs

---

Dose Frequency Patterns

Dosing frequency varies by compound and research context:

Compound	Common frequency in research
BPC-157	Once or twice daily
TB-500	Twice weekly (loading), then weekly
Ipamorelin	2–3x daily (timed to fasting periods)
CJC-1295 no DAC	2–3x daily (injected with ipamorelin)
CJC-1295 with DAC	Once weekly
GHK-Cu	Variable (daily to twice weekly referenced)
Semaglutide	Once weekly (mimicking pharmaceutical titration)

These frequencies reflect what is most commonly referenced in research protocols and community documentation. Specific studies may use different parameters.

---

Planning Total Vial Quantities for a Full Cycle

Before beginning a research cycle, it is useful to calculate how many vials you will need for the full protocol duration. This prevents running out mid-cycle.

Formula: Total mcg needed = Daily dose (mcg) x Doses per day x Protocol days

Then: Number of vials = Total mcg needed / mcg per vial

Example: BPC-157, 8-week cycle, 250 mcg twice daily

• Total mcg = 250 x 2 x 56 days = 28,000 mcg
• Vial size = 5 mg = 5,000 mcg
• Vials needed = 28,000 / 5,000 = 5.6, so 6 vials

Example: Ipamorelin, 8-week cycle, 200 mcg three times daily

• Total mcg = 200 x 3 x 56 = 33,600 mcg
• Vial size = 2 mg = 2,000 mcg
• Vials needed = 33,600 / 2,000 = 16.8, so 17 vials

The PepComputer calculator can help with per-dose calculations. Use the cycle quantity formula above for full-protocol planning.

---

Tracking Your Protocol

Organized documentation is important in research:

• Log each dose: date, time, compound, dose, units drawn, injection site
• Note reconstitution dates: to track the 30-day use-by window per vial
• Track vial inventory: know how many vials remain and project when you will need more
• Record observations: the purpose of structured research is to observe outcomes systematically

A simple notebook or spreadsheet works well. Consistency in record-keeping is more important than the specific system used.

---

Frequently Asked Questions

Q: Does the off period need to be a specific length? The rationale for off periods is receptor recovery, and the optimal duration is not precisely established in the literature. The rule of thumb of half the active cycle length (e.g., 2 weeks off after 4 weeks on) is referenced in many protocols as a practical starting point.

Q: Can I start a new cycle immediately if I ran short on a previous one? From a receptor biology standpoint, abrupt switches are generally not well-supported. The off period has a purpose. Running a short on-cycle and then immediately beginning another is generally not aligned with the cycling rationale.

Q: Do all peptides require cycling? Not all research protocols specify cycling for all compounds. BPC-157 in particular is sometimes used continuously in certain research designs. The general principle is that compounds working through specific receptors benefit more from cycling than compounds with more generalized mechanisms.

Q: How do I know if I need to order more vials before my cycle ends? Plan forward before beginning the cycle using the formula above. Order enough vials to complete the full on-phase before beginning, accounting for shipping time. Running out mid-cycle disrupts the protocol.